Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8563507 | Complementary Therapies in Medicine | 2018 | 8 Pages |
Abstract
High accessibility of vitamin D, as well as a growing lack of equipoise in patients and clinicians about the potential ubiquitous benefits of vitamin D for Canadians, not just for mood disorders, resulted in a large proportion of ineligible potential participants. Limited funding provided to studies on natural health products hampered recruitment. The labile and fluctuating nature of non-remitted depression as well as frequent co-morbid conditions creates additional challenges for conducting trials in this population. Future studies assessing vitamin D in depression should consider our experiences in design and conduct of research. Innovations in clinical trial design such as preference trials or accepting patients already using vitamin D but not achieving an optimal target value are potential solutions to some of these challenges.
Related Topics
Health Sciences
Medicine and Dentistry
Complementary and Alternative Medicine
Authors
Monique Aucoin, Kieran Cooley, Leena Anand, Melissa Furtado, Alex Canzonieri, Alexa Fine, Kathryn Fotinos, Ranjith Chandrasena, Larry J. Klassen, Irvin Epstein, Wende Wood, Martin A. Katzman,